Avelas Biosciences to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, June 13, 2017 – Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced that Carmine N. Stengone, president and chief executive officer, will be a panel participant at the JMP Securities Life Sciences Conference, being held in New York. The panel is titled, “Small Molecule Oncology Drugs: Challenges and Opportunities” and will take place at 1:00 p.m. EDT (10:00 a.m. PDT) on Tuesday, June 20, 2017.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company’s lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.